| Dr Charles Maxwell Medert, MD | |
|
2700 Bee Caves Rd, Austin, TX 78746-5642 | |
| (512) 250-2020 | |
| Not Available |
| Full Name | Dr Charles Maxwell Medert |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 7 Years |
| Location | 2700 Bee Caves Rd, Austin, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487195608 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 036.159124 (Illinois) | Secondary |
| 207W00000X | Ophthalmology | U2087 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Austin Eye Clinic Association | 6608910542 | 6 |
News Archive
A University of Alberta researcher's work to identify patients at greatest risk of prostate cancer cells spreading to another part of the body has earned a top award at a showcase of the world's best up-and-coming research talent.
In late 2015, former President Jimmy Carter announced that he was free of the metastatic melanoma that had spread to his liver and brain. In addition to surgery and radiation, Carter was treated with an immunotherapy drug, a new approach in cancer treatment that has a promising outlook.
Research by University of Iowa virologist Wendy Maury, PhD, has helped facilitate the launch of a new clinical trial in the United Kingdom of a drug that might help treat patients with COVID-19.
Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.
› Verified 7 days ago
| Entity Name | Austin Eye Clinic Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457540221 PECOS PAC ID: 6608910542 Enrollment ID: O20100216000829 |
News Archive
A University of Alberta researcher's work to identify patients at greatest risk of prostate cancer cells spreading to another part of the body has earned a top award at a showcase of the world's best up-and-coming research talent.
In late 2015, former President Jimmy Carter announced that he was free of the metastatic melanoma that had spread to his liver and brain. In addition to surgery and radiation, Carter was treated with an immunotherapy drug, a new approach in cancer treatment that has a promising outlook.
Research by University of Iowa virologist Wendy Maury, PhD, has helped facilitate the launch of a new clinical trial in the United Kingdom of a drug that might help treat patients with COVID-19.
Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles Maxwell Medert, MD 2700 Bee Caves Rd, Austin, TX 78746-5642 Ph: (512) 250-2020 | Dr Charles Maxwell Medert, MD 2700 Bee Caves Rd, Austin, TX 78746-5642 Ph: (512) 250-2020 |
News Archive
A University of Alberta researcher's work to identify patients at greatest risk of prostate cancer cells spreading to another part of the body has earned a top award at a showcase of the world's best up-and-coming research talent.
In late 2015, former President Jimmy Carter announced that he was free of the metastatic melanoma that had spread to his liver and brain. In addition to surgery and radiation, Carter was treated with an immunotherapy drug, a new approach in cancer treatment that has a promising outlook.
Research by University of Iowa virologist Wendy Maury, PhD, has helped facilitate the launch of a new clinical trial in the United Kingdom of a drug that might help treat patients with COVID-19.
Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.
› Verified 7 days ago
Dr. Kristen Michelle Hawthorne, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Saradha Chexal, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3705 Medical Pkwy Ste 460, Austin, TX 78705 Phone: 512-454-5851 | |
Dr. John David Fisher, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2901 Montopolis Dr, Austin, TX 78741 Phone: 512-389-6571 Fax: 512-389-6511 | |
Dr. Clio Armitage Harper Iii, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 W 38th St, Suite 200, Austin, TX 78705 Phone: 512-451-0103 Fax: 512-451-2741 | |
Dr. Nadja Ivette Torres, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2610 S Ih 35, Austin, TX 78704 Phone: 512-443-9715 Fax: 512-443-9845 | |
Fuad Makkouk, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9707 Anderson Mill Rd Ste 230, Austin, TX 78750 Phone: 512-693-9363 | |
Irina Volosko, DO Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3410 Far West Blvd Ste 140, Austin, TX 78731 Phone: 512-427-1107 Fax: 512-427-1207 |